ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1637

Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan

Jun Shimizu1, Yoshihisa Yamano1, Kimito Kawahata2 and Noboru Suzuki1, 1St. Marianna University School of Medicine, Kawasaki, Japan, 2Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

Meeting: ACR Convergence 2020

Keywords: cartilage, Epidemiology, Inflammation, Miscellaneous Rheumatic and Inflammatory Diseases, Pharmacoepidemiology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: We conducted a retrospective survey study in 2009 and collected clinical data of 239 patients with relapsing polychondritis (RP). Using the survey data, we found a strong inverse relationship between ear and airway involvement, suggesting that the two major clinical symptoms of RP occurred in a mutually exclusive manner (Arthritis Rheumatol. 2018). When we divided the patients into three subgroups, namely patients with airway involvement (A subgroup, 20% of 239 patients), patients with ear involvement (E subgroup, 49%), and patients with both ear and airway involvement (B subgroup, 29%), patients in B subgroup had more progressive and longer disease course (Medicine. 2018). Actually, 59% patients presented with ear involvement at disease onset and a third of the patients were allocated into B subgroup (patients with both ear and airway involvement) with a high mortality rate (BMC Rheumatol. 2020). To confirm the issue, we conducted 2nd nationwide survey in 2019.

Methods: The survey questionnaire was sent to Japanese major medical facilities and outpatient clinics in 2019. In this study, we analyzed clinical data of 128 patients with RP of the 2nd survey and made comparison with those of 239 patients with RP of the 1st survey.

Results: In 2019 survey, patient age, disease duration, and male to female ratio were 60.7 ± 1.36 years (57.4 ± 1.07 years in the 1st survey conducted 2009), 8.26 ± 0.74 years (4.76 ± 0.33 years), and 1.13:1 (1.13:1), respectively. The disease duration in 2019 survey was significantly longer than those in 2009 survey (p < 0.001). Numbers of the involved organs per-patient basis of 2019 survey were 1.30 ± 0.06 organs at disease onset and 3.09 ± 0.13 organs at the last follow-up (8.26 years). In 2009 survey, numbers of the involved organs at onset were 1.13 ± 0.02 organs and increased to 3.13 ± 0.09 organs at the last (4.76 years). The comparison suggests that the disease progressed modestly taking more time in 2019 survey. The prognostic stages tended to improve (from 2.45 ± 0.07 to 2.21 ± 0.07, p = 0.06) and the mortality rate declined significantly (from 9.2% to 2.3%, p = 0.01) in the 2019 survey compared with 2009 survey. At the last follow-up, incidence of ear (79% versus 89%, p = 0.02) and joint involvement (39% vs. 57%, p = 0.001) was significantly higher in 2019 survey than that in 2009 survey. Incidence of airway (49% vs. 28%, p = 0.001) and CNS (12% vs. 4.7%, p = 0.03) involvement was significantly lower in 2019 survey than that in 2009 survey. Use of immunosuppressants (except steroids) was significantly frequent in 2019 survey (59.4 ± 4.36%) than that in 2009 survey (37.2 ± 3.13%, p < 0.001).

Conclusion: In patients with RP, incidence of airway involvement and their mortality rate declined significantly during the decade in Japan. We are hard to exclude a possibility that RP spontaneously became mild in the decade. Nonetheless, our second survey suggests important implications of current treatment and/or management of RP, including advances of medications.


Disclosure: J. Shimizu, None; Y. Yamano, None; K. Kawahata, Pfizer Inc, 2, 5, 8; N. Suzuki, None.

To cite this abstract in AMA style:

Shimizu J, Yamano Y, Kawahata K, Suzuki N. Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/comparison-of-nation-wide-epidemical-study-on-2009-and-that-on-2019-revealed-that-improvement-of-disease-severity-and-mortality-rate-may-come-from-progress-of-proficient-management-in-patients-with-re/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-nation-wide-epidemical-study-on-2009-and-that-on-2019-revealed-that-improvement-of-disease-severity-and-mortality-rate-may-come-from-progress-of-proficient-management-in-patients-with-re/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology